文献速递妇科生殖医学

子宫内膜异位症患者血浆与腹腔液中自身抗体筛查

Autoantibody screening of plasma and peritoneal fluid of patients with endometriosis.
PubMed 文献 · Hum Reprod · 2023-01-01

本研究为多中心横断面研究,在波兰8个妇产科中心纳入137例子宫内膜异位症腹腔镜诊断患者,采用HuProt v3.1人类蛋白质组微阵列分析血浆和腹腔液自身抗体谱,未发现患者与对照组间自身抗体表达存在显著差异。

要点

  • 子宫内膜异位症患者血浆和腹腔液中自身抗体表达与对照组无显著差异。
  • Ⅱ期子宫内膜异位症患者腹腔液中ANAPC15和GABPB1自身抗体信号显著高于其他期别。
  • 子宫内膜异位症患者腹腔液中NEIL1、MAGEB4和TNIP2自身抗体信号在黄体期显著高于卵泡期。

核心结论

  • 本研究未发现子宫内膜异位症患者与对照组之间存在显著更高的自身抗体 prevalence。
  • 尽管子宫内膜异位症与不同自身免疫病相关,但由特定自身抗体介导的自身免疫反应不太可能在该炎症性疾病发病机制中起关键作用。

研究设计与样本

  • 多中心横断面研究,于2018年至2019年间在波兰多个城市的8个妇产科中心开展,历时18个月。
  • 纳入137例因诊断子宫内膜异位症接受腹腔镜检查的患者,术中获取137例血浆样本和98例腹腔液样本。
  • 排除患有自身免疫性疾病的患者,采用HuProt v3.1人类蛋白质组微阵列进行自身抗体谱分析。

主要发现

  • 子宫内膜异位症组与对照组血浆或腹腔液中自身抗体表达无显著差异。
  • Ⅱ期子宫内膜异位症患者腹腔液中ANAPC15和GABPB1反应性信号显著高于其他期别(adj. P < 0.016和adj. P < 0.026,两者logFC > 1)。
  • 子宫内膜异位症患者腹腔液中NEIL1(adj. P < 0.029)、MAGEB4(adj. P < 0.029)和TNIP2(adj. P < 0.042)自身抗体信号在黄体期显著高于卵泡期。
  • 血浆中未观察到月经周期两阶段间差异,子宫内膜异位症组与对照组之间亦无差异。
  • 腹腔液和血浆样本聚类未显示子宫内膜异位症特有的自身抗体谱,但同一患者腹腔液与血浆比较显示高度一致性。

临床怎么用

  • 作者认为,在寻找子宫内膜异位症生物标志物时,使用更高通量的蛋白质组微阵列可能更有效,或有助于发现潜在的新生物标志物。
  • 作者认为,只有开展此类规模的研究并可能采用不同技术,才能帮助发现改变子宫内膜异位症诊断方法的生物标志物。

局限性

  • 尽管本研究使用了可用的最高通量蛋白质阵列,但并未覆盖整个人类蛋白质组,且无法研究可能具有前景的翻译后修饰。
  • 自身抗体水平受感染等诸多因素影响,因此自身抗体检测应重复进行以获得更客观的结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Are there specific autoantibody profiles in patients with endometriosis that are different from those in controls? SUMMARY ANSWER: This study did not reveal a significantly higher prevalence of autoantibodies in the studied groups of patients. WHAT IS KNOWN ALREADY: Various inflammatory factors are postulated to be involved in the pathomechanisms of endometriosis, and a potential link exists with autoimmune diseases, which may also play an important role. As the diagnosis of endometriosis remains invasive, it can only be confirmed using laparoscopy with histopathological examination of tissues. Numerous studies have focused on identifying useful biomarkers to confirm the disease, but without unequivocal effects. Autoantibodies are promising molecules that serve as potential prognostic factors. STUDY DESIGN, SIZE, DURATION: A multicentre, cross-sectional study was conducted over 18 months (between 2018 and 2019), at eight Departments of Obstetrics and Gynaecology in several cities across Poland on 137 patients undergoing laparoscopic examination for the diagnosis of endometriosis. PARTICIPANTS/MATERIALS, SETTINGS, METHODS: During laparoscopy, we obtained plasma samples from 137 patients and peritoneal fluid (PF) samples from 98 patients. Patients with autoimmune diseases were excluded from the study. Autoantibody profiling was performed using HuProt v3.1 human proteome microarrays. MAIN RESULTS AND THE ROLE OF CHANCE: We observed no significant differences in the expression of autoantibodies in the plasma or PF between the endometriosis and control groups. The study revealed that in the PF of women with Stage II endometriosis, compared with other stages, there were significantly higher reactivity signals for ANAPC15 and GABPB1 (adj. P < 0.016 and adj. P < 0.026, respectively; logFC > 1 in both cases). Comparison of the luteal and follicular phases in endometriosis patients revealed that levels of NEIL1 (adj. P < 0.029), MAGEB4 (adj. P < 0.029), and TNIP2 (adj. P < 0.042) autoantibody signals were significantly higher in the luteal phase than in the follicular phase in PF samples of patients with endometriosis. No differences were observed between the two phases of the cycle in plasma or between women with endometriosis and controls. Clustering of PF and plasma samples did not reveal unique autoantibody profiles for endometriosis; however, comparison of PF and plasma in the same patient showed a high degree of concordance. LIMITATIONS, REASONS FOR CAUTION: Although this study was performed using the highest-throughput protein array available, it does not cover the entire human proteome and cannot be used to study potentially promising post-translational modifications. Autoantibody levels depend on numerous factors, such as infections; therefore the autoantibody tests should be repeated for more objective results. WIDER IMPLICATIONS OF THE FINDINGS: Although endometriosis has been linked to different autoimmune diseases, it is unlikely that autoimmune responses mediated by specific autoantibodies play a pivotal role in the pathogenesis of this inflammatory disease. Our study shows that in searching for biomarkers of endometriosis, it may be more efficient to use higher-throughput proteomic microarrays, which may allow the detection of potentially new biomarkers. Only research on such a scale, and possibly with different technologies, can help discover biomarkers that will change the method of endometriosis diagnosis. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by a grant from the Polish Ministry of Health (grant no. 6/6/4/1/NPZ/2017/1210/1352). It was also funded by the Estonian Research Council (grant PRG1076) and the Horizon 2020 Innovation Grant (ERIN; grant no. EU952516), Enterprise Estonia (grant no. EU48695), and MSCA-RISE-2020 project TRENDO (grant no. 101008193). The authors declare that there is no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Laudański P, Rogalska G, Warzecha D, et al. Autoantibody screening of plasma and peritoneal fluid of patients with endometriosis. Hum Reprod. 2023. PMID: 36749097. doi:10.1093/humrep/dead011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。